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Abstract
Development of reliable, easy-to-use, rapid diagnostic tests (RDTs) to detect glucose-6-phosphate dehydrogenase (G6PD)
deficiency at point of care is essential to deploying primaquine therapies as part of malaria elimination strategies. We
assessed a kit under research and development called CareStart
TM G6PD deficiency screening test (Access Bio, New Jersey,
USA) by comparing its performance to quantitative G6PD enzyme activity using a standardized spectrophotometric method
(‘gold standard’). Blood samples (n=903) were collected from Cambodian adults living in Pailin province, western
Cambodia. G6PD enzyme activities ranged from 0 to 20.5 U/g Hb (median 12.0 U/g Hg). Based on a normal haemoglobin
concentration and wild-type G6PD gene, the normal values of G6PD enzymatic activity for this population was 3.6 to 20.5 U/
g Hg (95
th percentiles from 5.5 to 17.2 U/g Hg). Ninety-seven subjects (10.7%) had ,3.6 U/g Hg and were classified as G6PD
deficient. Prevalence of deficiency was 15.0% (64/425) among men and 6.9% (33/478) among women. Genotype was
analyzed in 66 G6PD-deficient subjects and 63 of these exhibited findings consistent with Viangchang genotype. The
sensitivity and specificity of the CareStart
TM G6PD deficiency screening test was 0.68 and 1.0, respectively. Its detection
threshold was ,2.7 U/g Hg, well within the range of moderate and severe enzyme deficiencies. Thirteen subjects (1.4%, 12
males and 1 female) with G6PD enzyme activities ,2 U/g Hg were falsely classified as ‘‘normal’’ by RDT. This experimental
RDT test here evaluated outside of the laboratory for the first time shows real promise, but safe application of it will require
lower rates of falsely ‘‘normal’’ results.
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Introduction
In the context of malaria elimination, vector control measures
e.g. long lasting bednets and indoor residual spraying along with
prompt diagnosis and treatment of malaria infected patients are
the most effective tools currently available [1]. Antimalarial drugs
are seen as crucial to eliminate malaria and the focus is on the role
of drugs to block malaria transmission by killing gametocytes and
reducing the pool of liver hypnozoites of Plasmodium vivax and P.
ovale [2]. 8-aminoquinolines like primaquine (and tafenoquine, a
drug in phase III clinical trials) remain the only transmission-
blocking drugs available. While Artemisinin Combined Therapies
(ACTs) reduce gametocytogenesis in P. falciparum malaria by killing
young gametocytes, they lack activity against mature gametocytes
[3]. Therefore, primaquine remains a vitally important tool to
block the transmission of parasites, especially in areas like
Cambodia, where artemisinin resistant parasites are well docu-
mented [4,5,6]. Moreover, the 8-aminoquinolines are the only
effective drugs capable of killing P. vivax and P. ovale liver
hypnozoites, thereby, preventing relapses [7]. However, prima-
quine and tafenoquine cause predictable, intravascular haemolysis
in individuals with glucose-6-phosphate dehydrogenase (G6PD)
deficiency. Primaquine, at the transmission blocking dose (single
dose, 0.75 mg/kg), has been shown to cause haemolysis in P.
falciparum-infected African children without G6PD deficiency [8]
and to cause a greater initial fall in haemoglobin following
treatment compared to ACT alone [3]. High dose primaquine also
caused haemolysis in healthy, G6PD normal individuals [9]. This
dose of primaquine causes only slight drops in haemoglobin in
healthy African-American volunteers having the A- variant, but in
healthy volunteers having the B- Mediterranean variant, a
hemolysis of 25% of red blood cells occurs [10]. Thus, risk of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28357hemolysis with primaquine varies with status of both infection and
G6PD deficiency variant.
The conversion of NADP+ to NADPH by G6PD is the rate-
limiting reaction in the pentose phosphate pathway, the primary
source of reducing potential for the glutathione redox flux which
serves to as the primary protection of erythrocytes against oxidative
stress. Numerous drugs and chemicals such as primaquine, foods
(fava beans) or stress (infections) can induce hemolytic anemia in
G6PD-deficient individuals. G6PD deficiency is the second most
common hereditary enzyme deficiency which affects approximately
400 million people worldwide [11] and is distributed in areas of
current and previous endemic malaria [12]. This human enzyme
defect is caused by mutations in the G6PD gene located on
chromosome Xq28; thus, transmission of the genetic defect is X
linked. Hemizygote males are most affected and homozygous
females least affected; both are prone to red cell haemolysis.
Heterozygote females have mixed G6PD normal and deficient red
cells and their susceptibility to haemolysis depends on the balance
between the expression of the normal and abnormal X chromo-
somes[13].ThehighestfrequenciesaredetectedinAfrica,Southeast
Asia, Central and Southern Pacific islands, the Mediterranean
region, and in the Middle East [14]. There are some 140 different
genotypes of G6PD deficiency [15] with corresponding enzyme
activity phenotypes that vary from mild to severe. Primaquine
sensitivity phenotypes are known only in 3 variants; African A-,
Mahidol, and Mediterranean B-, representing mild, moderate and
severe sensitivity, respectively. Correlation between severity of
enzyme activity loss and sensitivity to primaquine is believed to
exist but has not been confirmed with clinical observations.
In Cambodia, G6PD deficiency is common, with a prevalence
ranging from 13.4% to 26.1% in males and 3.1% to 4.3% in
females, depending on the sampled population [16,17]. G6PD-
Viangchan is the most frequent variant [16,18].
G6PD deficiency may be diagnosed by a variety of spectropho-
tometric enzyme activity assays or DNA-based detection of specific
mutations. These tests, however, require relatively sophisticated
laboratory capacities. Qualitative tests for this disorder based upon
reduction of NADP+ by G6PD have been used for screening patients
in the absence of laboratory facilities prior to administration of
primaquine therapy. Since 1979, the fluorescent spot test is
recommended as the most suitable method for screening in the field,
despite the need for an UV lamp, water bath incubator, and
micropipettor [19,20]. Such equipment and the skills to use them are
rarely available in malaria endemics areas [8]. Consequently,
providersin such settings invite substantial risk of harm by prescribing
primaquine therapy and the drug is thus rarely used. Rapid
diagnostic tests (RDTs) are an alternative and attractive option
because they are generally easy to use and could be used alongside
malaria RDTs. However, the only available test named BinaxNOW
G6PD test
TM(ref 780-000, Binax, Inc., Maine, USA) which has been
recently evaluated, presents a major drawback with the need to
perform the test within a temperature ranging from 18 to 25uC,
imposing limited usefulness in tropical malaria-endemic countries
[21]. AccessBio (NewJersey, USA) hasdeveloped a new experimental
RDT called CareStart
TM G6PD deficiency screening test and its first
assessment outside of their laboratories is reported here, by
comparing its performance to the gold standard, quantitative
spectrophotometric estimation of G6PD enzyme activity [14].
Materials and Methods
Ethics statement
The study protocol was reviewed and approved by the National
Ethics Committee for Health Research of the Ministry of Health
of Cambodia (approval number 028 NECHR). Informed written
consent was provided by all individuals before inclusion in the
study and all investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Results for
each patient (according to the quantitative G6PD activity test)
were given to the local Ministry of Health staff of Pailin district
involved in the study. Participants were been notified of their
G6PD status. For deficient people, information regarding their
deficit was provided.
Population and Sample collection
A cross sectional survey was conducted in four malaria endemic
villages in Pailin Province in western Cambodia (Figure 1). After
informed consent was obtained, 2 ml of venous blood was
collected in EDTA-tube from healthy participants over 18 years
of age. Individuals with illness that affected competency to give
informed consent, along with pregnant or lactating women were
excluded from the study. Demographic information was gathered
by questionnaire. After collection, the fresh blood was used within
15 minutes to perform the CareStart
TM G6PD deficiency
screening test in the field, according to manufacturers’ instruc-
tions, and then sent to the Malaria Molecular Epidemiology Unit
at Pasteur Institute in Cambodia (IPC) in 4uC cool box within
24 hours. At IPC, the quantitative determination of G6PD
enzymatic activity was performed using 100 ml of fresh blood.
The remaining blood samples were centrifuged and aliquots of
plasma, buffy coat and red blood cells pellets were stored at
220uC for DNA analysis.
CareStart
TM G6PD deficiency screening test
The CareStart
TM G6PD deficiency screening test was provided
by the manufacturer (AccessBio, New Jersey, USA). The kit
contains the test strip encased in a flat plastic cassette (containing a
buffer well, a sample well and a result window), a sample pipette,
the assay buffer, an alcohol pad and a blood lancet. This RDT-
format test, which is not yet commercially available, is a qualitative
enzyme chromatographic test, based on the reduction of colorless
nitro blue tetrazolium dye to dark colored formazan. Following the
manufacturer instructions, two microliters of blood were added
into the sample well and two drops of buffer into the buffer well.
Test results were read visually after 10 minutes. Samples with
normal G6PD activity produce a distinct purple color background
in the result window while no color change was observed at the
test read time for samples with deficient G6PD activity (Figure 2).
Samples with a pale purple color background were classified as
normal. Long term temperature stability of the CareStart
TM
G6PD deficiency screening test for providing information about
RDT survival when used and stored outside the specified
temperatures was assessed following a modified procedure
described for malaria RDT lot testing Quality Control [22] by
using quality control (QC) materials (normal level, ref. G6888
deficient level ref. G5888 from Trinity Biotech). Briefly, RDT-
format tests were stored in incubators (35uC, 45uC and 55uC) with
daily temperature control. QC were repeated at D5, D10, D20,
D30, D60 and D90 for RDT-format tests stored at 35uc and 45uC
and at H4, H12, H24, H48 and H72 for RDT-format tests stored
at 55uC.
Quantitative determination of G6PD activity
Quantitative determination of G6PD activity was performed on
the fresh blood within a maximum of 48 h after the collection,
using the Trinity Biotech quantitative G6PD assay
TM (Ref. 345-
UV, Trinity Biotech, St. Louis, USA) adapted on the Integra
400
TM automate (Roche diagnostic, Meylan, France), according to
RDT for Screening G6PD Deficiency
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tion of the spectrophotometric methods of Kornberg and
Horecker [23] and of Lohr and Waller [24], involving the
reduction of NADP to NADPH by the G6PD enzyme in the
presence of glucose-6-phosphate and maleimide, acting as an
inhibitor of erythrocyte 6-phosphogluconate dehydrogenase (6-
PGDH). The formation of NADPH is proportional to the G6PD
activity and is measured spectrophotometrically as an increase in
absorbance at 340 nm. Reliability of test results were monitored
by calibration and the use of three different controls provided by
Trinity Biotech (deficient level ref. G5888, intermediate level ref.
G5029 and normal level, ref. G6888) within each run. Runs were
considered valid if control values fell within the given range. G6PD
activities were expressed in terms of amount of hemoglobin (U/g
Hg). Determination of hemoglobin content of the EDTA sample
was performed on a CellDyn 3200
TM analyser (Abbott, Rungis,
France) after standardization with three different controls. The
investigator and laboratory technicians running the quantitative
enzymatic assay were masked to the results of the CareStart
TM
G6PD deficiency screening test.
Detection of G6PD variants
Following the quantitative determination of G6PD activity and
using the normal ranges provided by Trinity Biotech (www.
trinitybiotech.com/Product% 20Documents/345-29%20EN.pdf),
sequencing of the G6PD gene was performed on all samples
classified as deficient (,4.6 U/g Hg) and a randomly selected
number of samples classified as normal ($4.6 U/g Hg).
DNA extraction
Human DNA was extracted from the buffy coat using the
QIAamp DNA Blood Mini Kit
TM (Qiagen, Courtaboeuf, France),
according to the manufacturer’s instructions.
DNA fragment amplification
Primers were designed to PCR amplify exons of the G6PD
gene, as shown in Table 1. The complete exonic regions were
generated in 8 fragments ranging between 221 and 848 bp. PCR
was performed in a 55 mL reaction containing 0.4 mM of each
specific primer, 0.25 mM of each dNTP, 1.5 to 2.5 mM MgCl2,
and 1.5 unit of FirePol Taq polymerase
TM (Solis Biodyne, Tartu,
Estonia). PCR cycling conditions were as follows: heating at 94uC
for 5 min, followed by 40 cycles of heating at 94uC for 30 s, 56–
58uC for 30–90 s and 72uC for 60–150 s, and a final extension
period at 72uC for 10 min.
Figure 2. Design of the CareStart
TM G6PD deficiency screening
test and interpretation of the results. Panel A, no color change for
sample with deficient G6PD enzymatic activity; Panel B, distinct purple
color for sample with normal G6PD enzymatic activity.
doi:10.1371/journal.pone.0028357.g002
Figure 1. Map of Cambodia locating the four selected villages in Pailin province, Cambodia, 2010.
doi:10.1371/journal.pone.0028357.g001
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After purification by filtration with a NucleoFast 96 PCR
plate
TM (Macherey-Nagel, Du ¨ren, Germany), sequencing reac-
tions were performed for both strands by using the ABI Prism
BigDye Terminator cycle sequencing ready reaction kit
TM run on
a 3730 xl genetic analyzer
TM (Applied Biosystems, Courtaboeuf,
France). Electrophoregrams were visualized and analyzed with
CEQ2000 genetic analysis system software
TM (Beckman Coulter,
Villepinte, France). Nucleotide sequences were compared to the
sequence of G6PD in GenBank (accession No. X55448) to identify
mutations.
Statistical analysis
Data were entered and verified using Microsoft Excel
TM
software, and analyzed using EpiInfo 6.04
TM software (CDC,
Atlanta, USA) and MedCalc
TM version 11.6.1 software (MedCalc,
Mariakerke, Belgium). The Mann-Whitney U test or Kruskal-
Wallis method were used for non-parametric comparisons, and
Student’s t test or one-way analysis of variance for parametric
comparisons. For categorical variables, Chi-squared or Fisher’s
exact tests were used to assess significant differences in
proportions. P values,0.05 indicated statistically significant
differences.
The mean, median, standard deviation and ranges were
determined for all G6PD enzyme activity values. The normal
values of G6PD enzymatic activity in Cambodian adults were
determined by gender from a subset of random samples classified
as normal using the quantitative G6PD assay ($4.6 U/g Hg) and
meeting the following criteria: hemoglobin concentration .12 g/
dL, and absence of genetic polymorphism compared to the
reference sequence: H. sapiens G6PD gene for glucose-6-phosphate
dehydrogenase, accession No. X55448. Distribution of normal
G6PD activity was evaluated by gender using Kolmogorov-
Smirnov test.
Subjects were also classed according to the WHO classifica-
tion for G6PD, using the population derived mean G6PD
enzyme activity as the reference for residual activity [14]: (i)
Class I (very severely deficient (associated with chronic non-
spherocytic hemolytic anaemia, ,1% residual activity,
,0.12 U/g Hg), (ii) Class II (severely deficient, 1 to 10%
residual activity, 0.13–1.2 U/g Hg), (iii) Class III (moderately
deficient, 10 to 60% residual activity, 1.3–7.1 U/g Hg), (iv) Class
IV (normal activity, 60 to 150% residual activity, 7.2–17.7 U/g
Hg) and (v) Class V (increased activity, .150% residual activity,
.17.7 U/g Hg).
To assess the performance of the CareStart
TM G6PD deficiency
screening test, individuals were grouped as G6PD deficient or
normal, using the normal values of G6PD enzymatic activity
determined in our Cambodian population. Standard diagnostic
test measures were determined: Sensitivity (Se) was the probability
that the CareStart
TM G6PD deficiency screening test classify
individuals as deficient among individuals classified as deficient by
using the quantitative G6PD assay (true positive rate). Specificity
(Sp) was the probability that the CareStart
TM G6PD deficiency
screening test classify individuals as normal among individuals
classified as normal by using the quantitative G6PD assay (true
negative rate). Positive Likelihood Ratio (PLR) was considered as
the ratio between the true positive rate and the false positive rate
(=sensitivity/[12Specificity]) and Negative Likelihood Ratio
(NLR) as the ratio between the false negative rate and the true
negative rate (=[12Sensitivity]/Specificity). Positive Predictive
Value (PPV) was the probability that G6PD deficiency was present
in individuals when the CareStart
TM G6PD deficiency screening
test classified individuals as deficient and Negative Predictive
Value (NPV), the probability that G6PD deficiency was not
present in individuals when the CareStart
TM G6PD deficiency
screening test classified individuals as normal. PPV and NPV were
calculated based on the prevalence (i.e. prior probability, PP) of
Table 1. Primers sequence, annealing temperatures and size of PCR products used to amplify and sequence exons of the G6PD
gene.
Exons Primer name Sequence (59-39) Hybridization T6
Size of PCR
products
Exon 2 PCR_G6PD_Ex2_F TGAAGGCTGCCTAGGAGAGA 58uC 494 bp
PCR_G6PD_Ex2_R CAGGTAGAGCCGGGATGAT
Exons 3–4 PCR_G6PD_Ex3–4_F TGTCCCCAGCCACTTCTAA 58uC 400 bp
PCR_G6PD_Ex3–4_R GGAGAGGAGGAGAGCATCC
Exon 5 PCR_G6PD_Ex 5_F CGGGGACACTGACTTCTG 56uC 500 bp
PCR_G6PD_Ex 5_R ACGCTGCCACCTTGTGGT
Exons 6–7 PCR_G6PD_Ex 6–7_F ACACAAGGCACGGGAGGT 58uC 697 bp
PCR_G6PD_Ex 6–7_R GAGGAGCTCCCCCAAGATAG
Exon 8 PCR_G6PD_Ex 8_F CCCTTGAACCAGGTGAACAG 58uC 221 bp
PCR_G6PD_Ex 8_R TCAGTGCCTCGTCACAGATG
Exon 9 PCR_G6PD_Ex 9_F CCTGAGGGCTGCACATCT 58uC 363 bp
PCR_G6PD_Ex 9_R GTGCGTGAGTGTCTCAGTGG
Exons 10–11–12 PCR_G6PD_Ex 10–12_F TGAGACACTCACGCACTGGT 58uC 752 bp
PCR_G6PD_Ex 10–12_R TGAGGTAGCTCCACCCTCAC
Exon 13 PCR_G6PD_Ex 13_F TTATGGCAGGTGAGGAAAGG 58uC 848 bp
PCR_G6PD_Ex 13_R GAAGTGGGTCCTCAGGGAAG
doi:10.1371/journal.pone.0028357.t001
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PPV=Se6PP/Se6PP+(12Sp)6(12PP) and NPV=Sp6(12PP)/
Sp6(12PP)+(12Se)6PP.
Results
Study population and distribution of the G6PD
enzymatic activity
From October to December 2010, nine hundred three blood
samples were collected in 4 villages in Pailin Province (Phitas Sbov
n=80; Andong Thmor, n=127; Oh Tantramdey, n=93 and
Pech Kiri, n=603). No significant differences were observed
between villages for sex ratio M/F (mean=0.89, P=0.74) and age
(mean=23.9 years, P=0.53), except for hemoglobin level
(mean=12.9 g/dL) which was lower in Pech Kiri compared to
Phitas Sbov (12.8 g/dL vs. 13.4 g/dL, P=0.03).
G6PD enzymatic activity values ranged from 0 to 20.9 U/g
Hg with arithmetic mean of 10.9 U/g Hg (95%CI: 10.6–11.2),
SD of 4.6 U/g Hg and median of 12.0 U/g Hg (95%CI: 11.9–
12.2). The distribution of G6PD enzymatic activity (Figure 3)
visually displays two different populations. No significant
differences were observed between gender and age. However,
significant differences were found between villages (P,0.01): the
lowest mean was observed in Phitas Sbov (7.4 U/g Hg,
SD=3.9 U/g Hg) and the highest in Pech Kiri (11.7 U/g Hg,
SD=5.2 U/g Hg).
Normal values of G6PD enzymatic activity in Cambodian
adults
Based on 147 normal samples (74 males and 73 females) as
described in Statistical analysis section, the normal range of G6PD
activity for all subjects was 3.6 to 20.5 U/g Hb; the lower limit of
normal was slightly lower for females (Table 2). G6PD values were
normally distributed for males (P=0.05) (Figure 4, Panel B). Mean
G6PD enzymatic activities were significantly higher for males
(P=0.005).
Prevalence & classification of G6PD deficiency
Based on the normal values of G6PD enzymatic activity defined
in our Cambodian population, the prevalence of G6PD deficiency
was 10.7% (97/903). Significant differences were observed
between the sexes: 64/425 (15.0%, CI95%: 11.6%–19.2%) for
males, and 33/478 (6.9%, CI95%: 4.7%–9.7%) for females,
P,0.001) and villages (9.3% in Pech Kiri, 10.2% in Andong
Thmor, 12.9% in Oh Tantramdey and 20.0% in Phitas Sbov,
P,0.001 ). According to the WHO classification, 1.2% (11/903)
individuals were classified as Class I, 5.6% (51/903) as Class II,
11.0% (99/9093) as Class III, 76.6% (691/903) as Class IV, and
5.6% (51/903) as Class V.
Genotyping data and major variants
Four different variants were detected among the 64 samples
used for sequencing of the G6PD gene. The most prevalent was
Figure 3. Distribution of the G6PD enzymatic activity (U/g Hb) values of 903 individuals enrolled in four villages of the Pailin
province, Cambodia, 2010.
doi:10.1371/journal.pone.0028357.g003
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1311C.T, IVS11 nt93T.C) followed by G6PD-Canton (fre-
quency 1.5%, 1/64, 1376G.T), G6PD-Mahidol (frequency 1.5%,
1/64, 487G.A) and G6PD-Valladolid (frequency 1.5%, 1/64,
406C.T, 1311C.T). Means 6 SD of G6PD enzymatic activity
in hemizygous males were 1.161.9 U/g Hg for the G6PD-
ViangChan variant (N=38), 0.2 U/g Hg for the G6PD-Canton
variant (N=1) and 3.3 U/g Hg for the G6PD-Valladolid variant
(N=1). For heterozygous females, means 6 SD of G6PD
enzymatic activity were 4.4 U/g Hg for the G6PD-Mahidol
variant (N=1) and 2.961.9 U/g Hg for the G6PD-ViangChan
variant (N=10). For homozygous females, mean 6 SD of G6PD
enzymatic activity of the G6PD-ViangChan variant (N=13) was
1.160.9 U/g Hg. Global distribution of the silent mutations,
1311C.T in exon 11 and T.C in nt93 in IVS11 in people with
normal G6PD enzymatic activity was 42.8%.
Table 2. Reference values for G6PD enzymatic activity (U/g Hg), Pailin province, Cambodia, 2010.
Reference values for
G6PD enzymatic activity Total Male Female
N 147 74 73
Range 3.6–20.5 4.3–20.5 3.6–18.9
Mean (95%CI), U/g Hg 11.8 (11.6–12.1) 12.5 (12.2–12.8) 11.3 (11.0–11.7)
SD, U/g Hg 2.7 2.5 2.6
Median (95%CI), U/g Hg 12.2 (12.0–12.4) 12.5 (12.3–12.7) 12.0 (11.5–12.0)
95
th percentiles, U/g Hg 5.5–17.2 6.5–17.9 5.6–15.5
N: Number of individuals; SD: Standard Deviation; 95%CI: 95% Confidence Interval.
doi:10.1371/journal.pone.0028357.t002
Figure 4. Distribution of the G6PD enzymatic activity (U/g Hb) reference values according to gender, of 147 G6PD-normal
individuals (see criteria in Statistical analysis section) enrolled in four villages of the Pailin province, Cambodia, 2010. (Panel A: Total
population, Panel B: Male population and Panel C: Female population).
doi:10.1371/journal.pone.0028357.g004
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TM G6PD deficiency
screening test
Distribution of G6PD enzymatic activity of our sampling
population according to the results of the CareStart
TM G6PD
deficiency screening test is given in the Figure 5. Results of the
CareStart
TM G6PD deficiency screening test and the quantitative
G6PD assay are also shown in Table 3.
The sensitivity of the CareStart
TM G6PD deficiency screening
test was 0.68 (CI95%: 0.58–0.77) and the specificity was 1.0
(CI95%: 0.99–1.0). Based on the 10.7% G6PD prevalence in our
study population, the NLR was 0.32 (CI95%: 0.24–0.43), the PLR
could not be calculated, the PPV was 1.0 (CI95%: 0.95–1.0) and
the NPV was 0.96 (CI95%: 0.95–0.97). The performance of the
CareStart
TM G6PD deficiency screening test was not significantly
different between genders (data not shown).
A totalof31falsenormalresultswereobservedinG6PD deficient
individuals with normal Hb concentrations: 4 males with G6PD
enzymatic activity was 0–0.9 U/g Hg, eight males and one female
with 1–1.9 U/g Hg, nine females and one male with 2–2.9 U/g Hg
and four females and three males with 3–3.5 U/g Hg. The
threshold of detection for the CareStart
TM G6PD deficiency
screening test to classifiy people as deficient was below 2.7 U/g Hg.
The evaluation of the long-term temperature stability of the
CareStart
TM G6PD deficiency screening test showed the test was
not affected by high temperatures. Similar performance was found
by using tests stored at 35uCo r4 5 uC for 90 days and at 55uC for
72 hours (data not shown).
Discussion
In many malaria endemic countries like Cambodia that are
engaging in malaria elimination, the introduction of primaquine,
for transmission blocking or radical cure, in national malaria
management guidelines remains a major safety challenge for
policy makers. The availability of an accurate, user-friendly, field-
adapted RDT for G6PD deficiency would be a major step
forward. The main advantages for using this drug are both the
prevention of P. falciparum transmission from malaria infected
patients by killing mature gametocytes and the radical cure P. vivax
(and P. ovale) infections by preventing relapses of the persistent liver
parasites [25]. However, it is well-known since 1956 [26], the use
of primaquine is not safe in people with erythrocyte glucose-6-
phosphate dehydrogenase deficiency. The most common clinical
manifestation is an acute hemolytic anaemia. Generally, the
residual G6PD enzyme activity correlates with the severity of
hemolysis, ranging from mild and transient to severe and life-
threatening [15]. Most of these data come from controlled studies
in which primaquine was given to G6PD deficient volunteers
(especially African A
2 variants) or normal recipients after
transfusion of
51Cr-labelled GPD-deficient red cells, and from
case reports of patients who developed hemolytic anaemia after
receiving primaquine. Therefore, beyond the routine use of
primaquine, comprehensive knowledge of the epidemiology of the
G6PD deficiency by using reliable methods is needed.
In this study, we have determined, for the first time, the normal
reference values of G6PD enzymatic activity for both Cambodian
Figure 5. Distribution of the G6PD enzymatic activity (U/g Hb) values, according to the CareStart
TM G6PD deficiency screening test
results of 903 individuals enrolled in four villages of the Pailin province, Cambodia, 2010.
doi:10.1371/journal.pone.0028357.g005
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metric assay. Reference ranges generally used are derived from
North American or European populations which may not be
applicable to the Cambodian population. For this purpose, healthy
individuals (Khmer ethnic group) were selected with a normal
range of hemoglobin concentration and a wild-type sequence in
their G6PD gene.
Surprisingly, we found that globally G6PD enzymatic activity
was significantly higher in males compared to females (12.5 vs.
11.3 U/g Hg, P=0.005) while previous reports showed no
difference using the same methodology [27]. Using these values,
the global prevalence of G6PD deficiency in our sample
population was 10.7%, ranging from 9.3% in the most southern
village to 20% in the most northern village of the Pailin province.
The cut-off point to diagnose G6PD deficiency both in
Cambodian males and females was around 30% of the normal
mean value. As expected [28], we found that the prevalence of
G6PD deficiency was almost 2-fold higher in males (15.0%)
compared to females (6.9%). This proportion was similar to
previous reports from Cambodia [16,17,18,29] and in the
bordering countries of Vietnam, Laos and Thailand [28].
Molecular analysis of G6PD variants in deficient people
indicated that the most prevalent variant was G6PD-ViangChan,
in concordance with previous reports showing that G6PD-
ViangChan variant is relatively homogeneous in Cambodians
and Laotians in the Eastern part of the Southeast Asian peninsular
while G6PD-Mahidol variant is predominant in Myanmar
population in the Western part of the peninsular. Moreover, all
cases of G6PD-ViangChan (871G.A) were linked to 1311C.T
on exon 11 and T.C in nt93 on IVS11, as previously described in
neighboring countries [27,30,31]. In addition, 1311C.T on exon
11 and T.C in nt93 on IVS11 mutations were not only restricted
to G6PD-ViangChan variant since they were observed in 42.8%
of people presenting wild type sequence in their G6PD gene,
supporting the notion that these sites are highly polymorphic and
the occurrence of the mutations is widespread. G6PD-Union
(1360C.T) and G6PD-Coimbra (592C.T) which has been
already detected in G6PD-deficient Cambodians were not
identified [16,18] but contrary to these two previous reports we
observed for the first time in Cambodia G6PD-Mahidol
(487G.A), G6PD Canton (1376G.T) and G6PD-Valladolid
(406 C.T).
In our study, we have shown that the CareStart
TM G6PD
deficiency screening test had relatively low sensitivity and high
specificity. The kit was able to detect G6PD deficiency at an
enzyme activity threshold of ,2.7 U/g Hg. This represents a cut-
off value of 22% of G6PD normal activity and translates into an
ability to detect individuals with severe enzyme deficiency (WHO
Classes I and II and some Class III variants). This performance
was similar to that classically described for the fluorescent spot
method, method recommended since 1979 as screening test, by
the International Committee for Standardization in Hematology
[32]. Individuals with intermediate or mild G6PD deficiency (from
3.6 to 2.7 U/g Hg, 22%–30% of normal activity) were not
identified as deficient by the RDT. For instance, only 40% of
G6PD-ViangChan heterozygote females were identified as
deficient. Whether this would pose a hazard or an advantage in
screening for primaquine therapy depends upon the relative
sensitivity to primaquine exhibited by such patients. This
important question requires clinical investigation as part of the
validation process of this RDT.
The 13 false negative results (12 males and one female) with a
G6PD enzymatic activity ,2 U/g Hg require careful consider-
ation as an important safety issue. Such individuals would
inappropriately receive primaquine and be at risk of clinically
significant hemolysis. We systematically classified test results
showing any purple color, even if pale, as normal. This may
explain the false negatives reported here, and if so, a more
conservative approach of classifying ambiguous RDT results as
deficient would perhaps have improved sensitivity and diminished
specificity. As a clinical safety issue, that would be the preferred
approach. In any event, the developers of this RDT may consider
a design of that permits visualization of both positive & negative
control color changes on each cassette. Assuming the sensitivity
reported here may be thus dramatically improved, the CareS-
tart
TM G6PD deficiency screening test appears otherwise ideal for
use in endemic zones, in particular its apparent robust perfor-
mance after prolonged storage at high temperatures.
In conclusion, the CareStart
TM G6PD deficiency screening test
is a new tool under development for screening G6PD deficiency in
the field which presents all the advantages of a point-of-care such
as fast and easy to perform, without requiring electricity or specific
equipment. The first evaluation of this test ‘‘outside of the
laboratory’’ showed its capability of detecting severe deficiency as
the fluorescent spot test but improvement in sensitivity is
recommended. In parallel, more clinical data on the optimal
primaquine doses for malaria elimination are needed urgently in
order to improve the developpement of the next generation of tests
which will aim at providing a reliable and safe ‘‘go vs. no-go’’
decision to safetly use primaquine in routine.
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